LUMOS DIAGNOSTICS HOLDINGS LIMITED (LDX)

Latest AI Signal: SELL
Status: NEW
Days Old: 3

Confidence: 75.00%

Date: 18-05-2026

Price: $0.125

Last Price: $0.130

Post-Signal Low Price: $0.125

Latest  LUMOS DIAGNOSTICS HOLDINGS LIMITED(LDX)   News

16 Apr 2026, 02:44 AM

Lumos sets Q3 reporting date, investor webinar as SPP enters final stretch

Lumos sets Q3 reporting date, investor webinar as SPP enters final stretch Proactive uses images sourced from Shutterstock Lumos Diagnostics Holdings Ltd (ASX:LDX, OTC:LDXHF) has locked in the timing for its March quarter update and investor briefing, while reminding shareholders that its current c

14 Apr 2026, 09:18 PM

Lumos secures US$5m FebriDx milestone payment as US rollout gains traction

Lumos secures US$5m FebriDx milestone payment as US rollout gains traction Proactive uses images sourced from Shutterstock Lumos Diagnostics Holdings Ltd (ASX:LDX, OTC:LDXHF) has received a US$5 million milestone pre-payment from its US distribution partner Phase Scientific, with its FebriDx® point

27 Feb 2026, 10:31 AM

Lumos lifts operating cash flow on FebriDx momentum as 1H FY26 loss widens

Lumos lifts operating cash flow on FebriDx momentum as 1H FY26 loss widens Proactive uses images sourced from Shutterstock Lumos Diagnostics Holdings Ltd (ASX:LDX, OTC:LDXHF) has reported revenue of US$6.12 million for the six months to December 31, 2025 (1H FY26), down slightly from US$6.31 millio

21 Jun 2022, 10:01 PM

Lumos Diagnostics Appoints Doug Ward as CEO

SARASOTA, Fla., June 21, 2022 (GLOBE NEWSWIRE) -- Lumos Diagnostics (ASX:LDX), a leader in rapid point-of-care (POC) diagnostic technologies, announced today that its Board of Directors has appointed Doug Ward, a highly experienced diagnostics executive, to serve as CEO. “We are delighted to welc

Chart available once enough post-signal price data is available.

Sell Confidence High

AI Confidence - 75.00 % model confidence

Business Overview

Lumos Diagnostics Holdings Limited develops and markets rapid diagnostic testing technologies primarily for infectious diseases. The company operates in the growing point-of-care diagnostics market, targeting healthcare providers and laboratories with innovative, easy-to-use testing solutions. Its market position is emerging with a focus on expanding product offerings and geographic reach.

Financial Analysis

Cash Flow	Weak
Debt	Moderate
Profitability	Weak
Revenue Trend	Downtrend

Technical Analysis

Trend	Bearish
Momentum	Weak
RSI Signal	Oversold
Support Level	$ 0.12
Resistance Level	$ 0.15

Valuation

Valuation - Overvalued

Current price reflects high risk and weak fundamentals despite low absolute price, limiting upside potential.

Catalysts

• Potential new product launches or regulatory approvals could provide upside.

• Strategic partnerships or capital raises to improve liquidity and market presence.

Recommendation

Action - Sell

Timeframe - Short Term

Given weak financials, bearish technical signals, and limited near-term catalysts, LDX shares are likely to underperform. Investors should consider reducing exposure to mitigate downside risk.